Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas

Filip Y De Vos; Johanna M Gijtenbeek; Chantal P Bleeker-Rovers; Carla M van Herpen

doi:10.1016/j.critrevonc.2012.08.002

Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas

Crit Rev Oncol Hematol. 2013 Mar;85(3):373-82. doi: 10.1016/j.critrevonc.2012.08.002. Epub 2012 Aug 25.

Authors

Filip Y De Vos¹, Johanna M Gijtenbeek, Chantal P Bleeker-Rovers, Carla M van Herpen

Affiliation

¹ Department of Medical Oncology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. f.devos@umcutrecht.nl

PMID: 22925496
DOI: 10.1016/j.critrevonc.2012.08.002

Abstract

High-grade glioma patients receiving concomitant chemoradiotherapy with temozolomide 75mg/m(2) during six to seven weeks or dose-dense temozolomide regimens especially in combination with chronic use of corticosteroids have a high risk for developing Pneumocystis jirovecii pneumonia. In this review, we define risk groups and propose a guideline for prophylaxis using risk stratification.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / therapeutic use
Antibiotic Prophylaxis*
Antineoplastic Agents, Alkylating / adverse effects*
Antineoplastic Agents, Alkylating / therapeutic use
Dacarbazine / adverse effects
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Glioma / complications*
Glioma / drug therapy
Glioma / pathology
Humans
Neoplasm Grading
Pneumocystis carinii* / immunology
Pneumonia, Pneumocystis / complications*
Pneumonia, Pneumocystis / prevention & control*
Risk Factors
Temozolomide

Substances

Anti-Bacterial Agents
Antineoplastic Agents, Alkylating
Dacarbazine
Temozolomide